| Dr Tim Arakawa, MD, PHD | |
|
3615 Nw Samaritan Dr Ste G2, Corvallis, OR 97330-3783 | |
| (541) 768-7900 | |
| Not Available |
| Full Name | Dr Tim Arakawa |
|---|---|
| Gender | Male |
| Speciality | Endocrinology |
| Experience | 15 Years |
| Location | 3615 Nw Samaritan Dr Ste G2, Corvallis, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841421229 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Regional Medical Center | Corvallis, OR | Hospital |
| Samaritan Albany General Hospital | Albany, OR | Hospital |
| Samaritan Lebanon Community Hospital | Lebanon, OR | Hospital |
| Samaritan Pacific Community Hospital | Newport, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Albany General Hospital | 9931097987 | 162 |
| Good Samaritan Hospital Corvallis | 1557270725 | 339 |
| Mid-valley Healthcare Inc | 2769391523 | 134 |
News Archive
At some point in their lives, 15 percent of people with diabetes will develop a painful and hard-to-treat foot ulcer.
Magellan Health Services Inc. today reported financial results for the second quarter of 2011, as summarized below. For the quarter ended June 30, 2011, the company reported net revenue of $698.3 million, segment profit of $75.9 million, and net income of $34.2 million or $1.07 per diluted common share.
TLC Vision Corporation (NASDAQ: TLCV) (TSX: TLC) announced today that, on September 16, 2009, it received letters from The Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the Company's common stock has not maintained a minimum value of publicly held shares of $15 million as required by Marketplace Rule 5450(b)(2)(C) or 5450(b)(3)(C) (the "MVPHS Rule") and the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 5450(a)(1) (the "Minimum Bid Price Rule").
Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine.
› Verified 3 days ago
| Entity Name | Mid-valley Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689625980 PECOS PAC ID: 2769391523 Enrollment ID: O20031111000297 |
News Archive
At some point in their lives, 15 percent of people with diabetes will develop a painful and hard-to-treat foot ulcer.
Magellan Health Services Inc. today reported financial results for the second quarter of 2011, as summarized below. For the quarter ended June 30, 2011, the company reported net revenue of $698.3 million, segment profit of $75.9 million, and net income of $34.2 million or $1.07 per diluted common share.
TLC Vision Corporation (NASDAQ: TLCV) (TSX: TLC) announced today that, on September 16, 2009, it received letters from The Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the Company's common stock has not maintained a minimum value of publicly held shares of $15 million as required by Marketplace Rule 5450(b)(2)(C) or 5450(b)(3)(C) (the "MVPHS Rule") and the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 5450(a)(1) (the "Minimum Bid Price Rule").
Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine.
› Verified 3 days ago
| Entity Name | Good Samaritan Hospital Corvallis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962453134 PECOS PAC ID: 1557270725 Enrollment ID: O20031125000163 |
News Archive
At some point in their lives, 15 percent of people with diabetes will develop a painful and hard-to-treat foot ulcer.
Magellan Health Services Inc. today reported financial results for the second quarter of 2011, as summarized below. For the quarter ended June 30, 2011, the company reported net revenue of $698.3 million, segment profit of $75.9 million, and net income of $34.2 million or $1.07 per diluted common share.
TLC Vision Corporation (NASDAQ: TLCV) (TSX: TLC) announced today that, on September 16, 2009, it received letters from The Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the Company's common stock has not maintained a minimum value of publicly held shares of $15 million as required by Marketplace Rule 5450(b)(2)(C) or 5450(b)(3)(C) (the "MVPHS Rule") and the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 5450(a)(1) (the "Minimum Bid Price Rule").
Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine.
› Verified 3 days ago
| Entity Name | Samaritan North Lincoln Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306897491 PECOS PAC ID: 7911816301 Enrollment ID: O20040120000329 |
News Archive
At some point in their lives, 15 percent of people with diabetes will develop a painful and hard-to-treat foot ulcer.
Magellan Health Services Inc. today reported financial results for the second quarter of 2011, as summarized below. For the quarter ended June 30, 2011, the company reported net revenue of $698.3 million, segment profit of $75.9 million, and net income of $34.2 million or $1.07 per diluted common share.
TLC Vision Corporation (NASDAQ: TLCV) (TSX: TLC) announced today that, on September 16, 2009, it received letters from The Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the Company's common stock has not maintained a minimum value of publicly held shares of $15 million as required by Marketplace Rule 5450(b)(2)(C) or 5450(b)(3)(C) (the "MVPHS Rule") and the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 5450(a)(1) (the "Minimum Bid Price Rule").
Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine.
› Verified 3 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174888010 PECOS PAC ID: 2466353529 Enrollment ID: O20040204000304 |
News Archive
At some point in their lives, 15 percent of people with diabetes will develop a painful and hard-to-treat foot ulcer.
Magellan Health Services Inc. today reported financial results for the second quarter of 2011, as summarized below. For the quarter ended June 30, 2011, the company reported net revenue of $698.3 million, segment profit of $75.9 million, and net income of $34.2 million or $1.07 per diluted common share.
TLC Vision Corporation (NASDAQ: TLCV) (TSX: TLC) announced today that, on September 16, 2009, it received letters from The Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the Company's common stock has not maintained a minimum value of publicly held shares of $15 million as required by Marketplace Rule 5450(b)(2)(C) or 5450(b)(3)(C) (the "MVPHS Rule") and the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 5450(a)(1) (the "Minimum Bid Price Rule").
Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine.
› Verified 3 days ago
| Entity Name | Albany General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154372340 PECOS PAC ID: 9931097987 Enrollment ID: O20040310000310 |
News Archive
At some point in their lives, 15 percent of people with diabetes will develop a painful and hard-to-treat foot ulcer.
Magellan Health Services Inc. today reported financial results for the second quarter of 2011, as summarized below. For the quarter ended June 30, 2011, the company reported net revenue of $698.3 million, segment profit of $75.9 million, and net income of $34.2 million or $1.07 per diluted common share.
TLC Vision Corporation (NASDAQ: TLCV) (TSX: TLC) announced today that, on September 16, 2009, it received letters from The Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the Company's common stock has not maintained a minimum value of publicly held shares of $15 million as required by Marketplace Rule 5450(b)(2)(C) or 5450(b)(3)(C) (the "MVPHS Rule") and the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 5450(a)(1) (the "Minimum Bid Price Rule").
Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine.
› Verified 3 days ago
| Entity Name | Samaritan North Lincoln Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1306897491 PECOS PAC ID: 7911816301 Enrollment ID: O20061104000117 |
News Archive
At some point in their lives, 15 percent of people with diabetes will develop a painful and hard-to-treat foot ulcer.
Magellan Health Services Inc. today reported financial results for the second quarter of 2011, as summarized below. For the quarter ended June 30, 2011, the company reported net revenue of $698.3 million, segment profit of $75.9 million, and net income of $34.2 million or $1.07 per diluted common share.
TLC Vision Corporation (NASDAQ: TLCV) (TSX: TLC) announced today that, on September 16, 2009, it received letters from The Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the Company's common stock has not maintained a minimum value of publicly held shares of $15 million as required by Marketplace Rule 5450(b)(2)(C) or 5450(b)(3)(C) (the "MVPHS Rule") and the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 5450(a)(1) (the "Minimum Bid Price Rule").
Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine.
› Verified 3 days ago
| Entity Name | Mid-valley Healthcare Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1689625980 PECOS PAC ID: 2769391523 Enrollment ID: O20061104000140 |
News Archive
At some point in their lives, 15 percent of people with diabetes will develop a painful and hard-to-treat foot ulcer.
Magellan Health Services Inc. today reported financial results for the second quarter of 2011, as summarized below. For the quarter ended June 30, 2011, the company reported net revenue of $698.3 million, segment profit of $75.9 million, and net income of $34.2 million or $1.07 per diluted common share.
TLC Vision Corporation (NASDAQ: TLCV) (TSX: TLC) announced today that, on September 16, 2009, it received letters from The Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the Company's common stock has not maintained a minimum value of publicly held shares of $15 million as required by Marketplace Rule 5450(b)(2)(C) or 5450(b)(3)(C) (the "MVPHS Rule") and the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 5450(a)(1) (the "Minimum Bid Price Rule").
Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine.
› Verified 3 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1801847066 PECOS PAC ID: 2466353529 Enrollment ID: O20061104000163 |
News Archive
At some point in their lives, 15 percent of people with diabetes will develop a painful and hard-to-treat foot ulcer.
Magellan Health Services Inc. today reported financial results for the second quarter of 2011, as summarized below. For the quarter ended June 30, 2011, the company reported net revenue of $698.3 million, segment profit of $75.9 million, and net income of $34.2 million or $1.07 per diluted common share.
TLC Vision Corporation (NASDAQ: TLCV) (TSX: TLC) announced today that, on September 16, 2009, it received letters from The Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the Company's common stock has not maintained a minimum value of publicly held shares of $15 million as required by Marketplace Rule 5450(b)(2)(C) or 5450(b)(3)(C) (the "MVPHS Rule") and the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 5450(a)(1) (the "Minimum Bid Price Rule").
Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tim Arakawa, MD, PHD Po Box 1189, Corvallis, OR 97339-1189 Ph: () - | Dr Tim Arakawa, MD, PHD 3615 Nw Samaritan Dr Ste G2, Corvallis, OR 97330-3783 Ph: (541) 768-7900 |
News Archive
At some point in their lives, 15 percent of people with diabetes will develop a painful and hard-to-treat foot ulcer.
Magellan Health Services Inc. today reported financial results for the second quarter of 2011, as summarized below. For the quarter ended June 30, 2011, the company reported net revenue of $698.3 million, segment profit of $75.9 million, and net income of $34.2 million or $1.07 per diluted common share.
TLC Vision Corporation (NASDAQ: TLCV) (TSX: TLC) announced today that, on September 16, 2009, it received letters from The Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the Company's common stock has not maintained a minimum value of publicly held shares of $15 million as required by Marketplace Rule 5450(b)(2)(C) or 5450(b)(3)(C) (the "MVPHS Rule") and the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 5450(a)(1) (the "Minimum Bid Price Rule").
Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine.
› Verified 3 days ago
Tomer Pelleg, Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3600 Nw Samaritan Dr Ste 227, Corvallis, OR 97330 Phone: 541-768-1261 | |
Dr. Parinav Kanwar, Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 3600 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-768-4906 | |
Dr. Stanley J. Nudelman, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3521 Nw Samaritan Dr, Suite 201, Corvallis, OR 97330 Phone: 541-768-5140 | |
Dr. Randall V. Bream, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 3600 Nw Samaritan Dr, Suite E350, Corvallis, OR 97330 Phone: 541-768-5205 Fax: 541-768-5206 | |
Jonathan David Jones, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3620 Nw Samaritan Dr Ste 202, Corvallis, OR 97330 Phone: 541-768-5800 | |
Gemechu Abraham Geleto, Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 3600 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-768-4906 | |
Roland Solensky, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3680 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-754-1150 |